Konark Intelmed Limited Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: Konark Intelmed Limited Pharmaceutical Import Records from India — 2 Products, $1.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Konark Intelmed Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $1.4M Trade | TransData Nexus

Konark Intelmed Limited

Pharmaceutical Importer · Poland · Respiratory & OTC Focus · $1.4M Total Trade · DGFT Verified

Konark Intelmed Limited is a pharmaceutical importer based in Poland with a total trade value of $1.4M across 2 products in 2 therapeutic categories. Based on 86 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Konark Intelmed Limited sources from 1 verified Indian supplier, with Euro Lifecare Private Limited accounting for 100.0% of imports.

Konark Intelmed Limited — Import Portfolio & Supplier Network

Konark Intelmed Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Konark Intelmed Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Euro Lifecare Private Limited	$10.1M	808	100.0%

Konark Intelmed Limited sources from 1 verified Indian supplier across 477 distinct formulations. The sourcing is highly concentrated — Euro Lifecare Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Gripout hot drink powder for oral	$554.7K	20
Medicines of indian origin item	$368.9K	18
Azithromycin euro, Film-Coated tablets	$257.3K	7
Medicines of indian origin item	$250.0K	5
Herbal product of indian origin item-	$246.5K	16
Eurofast express soft capsules, 400 MG	$212.9K	5
Doloxen tablets, Film-Coated	$212.7K	5
Gripout hot drink powder for oral solution 6g per sachets no. 10 (paracetamol, pheniramine maleate, phenylephrine hcl	$187.4K	11
Herbal product of indian origin item -	$174.9K	12
Pantozole enteric-coated tablets 40 mg10 tablets in blisters; 3 blisters in acardboard pantoprazole tablets 40MG	$149.2K	4
Eurofast softcaps soft capsules, 400 MG,10 capsules in a blister, 2 blisters ina cardboard Box (ibuprofen 400 MG)	$149.0K	4
Medicines of indian origin item	$135.3K	4
Medicines of indian origin item	$129.8K	5
Eurofast softcaps soft capsules, 400 MG,10 capsules in a blister, 2 blisters ina cardboard Box (ibuprofen 400 MG	$122.6K	4
Pantozole enteric coated tablets 40 MG 10 tablets in blisters 3 blisters in acardboard pantoprazole tablets 40MG	$119.0K	3

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Phenylephrine	Respiratory & OTC	$1.2M	66	1.5%	14
2	Ranitidine	Gastrointestinal	$191.5K	20	1.5%	13

Konark Intelmed Limited imports 2 pharmaceutical products across 2 categories into Poland totaling $1.4M.

Konark Intelmed Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Konark Intelmed Limited is a pharmaceutical importer and distributor based in Poland, specializing in the procurement and distribution of finished pharmaceutical formulations. The company has established itself as a key player in Poland's pharmaceutical supply chain, focusing on sourcing high-quality medical drugs from reputable global manufacturers. With a commitment to enhancing the quality of life through innovative healthcare solutions, Konark Intelmed Limited plays a pivotal role in ensuring the availability of essential medications across Poland.

2Distribution Network

While specific details about Konark Intelmed Limited's warehouse locations and logistics capabilities are not publicly disclosed, the company is known for its efficient distribution network within Poland. This network ensures timely delivery of pharmaceutical products to various healthcare facilities, pharmacies, and medical institutions nationwide. The company's strategic partnerships with global manufacturers enable it to maintain a steady supply of essential medications, meeting the diverse needs of the Polish healthcare sector.

3Industry Role

Konark Intelmed Limited operates primarily as a pharmaceutical importer and distributor within Poland's pharmaceutical supply chain. By sourcing finished pharmaceutical formulations from international manufacturers, the company ensures the availability of a wide range of medications in the Polish market. Its role is crucial in bridging the gap between global pharmaceutical producers and the local healthcare system, facilitating access to essential drugs for patients and healthcare providers across Poland.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Konark Intelmed Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Konark Intelmed Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, EURO LIFECARE PRIVATE LIMITED. This concentrated sourcing approach may present certain risks, such as potential supply chain disruptions if issues arise with the primary supplier. However, it also suggests a strategic choice to establish a strong, reliable partnership with a trusted supplier, ensuring consistent product quality and availability. The company's substantial import value from India indicates a well-established and stable relationship with EURO LIFECARE PRIVATE LIMITED, which is essential for maintaining a steady supply of pharmaceutical products.

2Supply Chain Resilience

The resilience of Konark Intelmed Limited's supply chain is closely tied to its relationship with EURO LIFECARE PRIVATE LIMITED. While the company imports a diverse range of 477 unique pharmaceutical formulations, the heavy reliance on a single supplier may pose challenges in terms of supply chain flexibility and risk management. To enhance resilience, it would be prudent for Konark Intelmed Limited to consider diversifying its supplier base and establishing relationships with additional manufacturers. This strategy would mitigate potential risks associated with supply chain disruptions and ensure a more robust and adaptable supply chain capable of meeting the dynamic demands of the Polish pharmaceutical market.

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Chief Pharmaceutical Inspectorate (Główny Inspektorat Farmaceutyczny, GIF) serves as the primary regulatory authority overseeing the import and distribution of medicinal products. The Pharmaceutical Law of 6 September 2001, along with subsequent amendments, provides the legal framework governing the importation, marketing, and distribution of pharmaceutical products in Poland. This legislation outlines the requirements for obtaining import licenses, ensuring product quality, and maintaining compliance with Good Manufacturing Practice (GMP) standards. For Indian pharmaceutical exporters, understanding and adhering to these regulations is crucial for successful market entry and sustained operations within Poland.

2Import Licensing & GMP

Import licensing in Poland is regulated under the Pharmaceutical Law, which stipulates that entities involved in the importation of medicinal products must obtain authorization from the Chief Pharmaceutical Inspectorate. This process ensures that imported products meet the necessary quality and safety standards. Poland recognizes GMP certificates from the European Union (EU), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian pharmaceutical exporters seeking to supply Konark Intelmed Limited must ensure that their manufacturing facilities hold valid GMP certifications from these recognized bodies. Additionally, obtaining wholesale distribution authorization is essential for legal distribution within Poland, necessitating compliance with Polish regulatory requirements and standards.

Konark Intelmed Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Konark Intelmed Limited's focus on importing pharmaceutical products in the respiratory and over-the-counter (OTC) therapeutic categories aligns with the significant demand for these medications in Poland. The high import value of phenylephrine and ranitidine indicates a strategic emphasis on addressing prevalent health concerns such as respiratory issues and gastrointestinal disorders. This product strategy reflects the company's commitment to meeting the healthcare needs of the Polish population by providing accessible and effective treatment options.

2Sourcing Profile

Konark Intelmed Limited's sourcing strategy is centered on importing generic pharmaceutical products from India, focusing on finished formulations rather than active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows the company to offer a diverse range of medications that are both cost-effective and of high quality. India's robust pharmaceutical manufacturing sector, known for its adherence to international quality standards, makes it a preferred sourcing destination for Konark Intelmed Limited.

3Market Positioning

Seller's Guide — How to Become a Supplier to Konark Intelmed Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Konark Intelmed Limited, particularly in the respiratory and gastrointestinal therapeutic categories. The company's substantial import value from India and its focus on these therapeutic areas indicate a sustained demand for such products. New suppliers can explore this opportunity by ensuring compliance with Polish regulatory standards, obtaining the necessary certifications, and establishing reliable supply chains to meet the quality and delivery expectations of Konark Intelmed Limited.

2Requirements & Qualifications

Indian pharmaceutical exporters aiming to supply Konark Intelmed Limited and the Polish market must ensure that their manufacturing facilities hold valid GMP certifications recognized by the EU, WHO, or PIC/S. Additionally, obtaining wholesale distribution authorization from the Chief Pharmaceutical Inspectorate is essential for legal distribution within Poland. Compliance with Polish labeling requirements, including the use of the Polish language and adherence to serialization mandates, is also necessary to meet regulatory expectations and facilitate market entry.

3How to Approach

Frequently Asked Questions — Konark Intelmed Limited

What products does Konark Intelmed Limited import from India?

Konark Intelmed Limited imports 2 pharmaceutical products across 2 categories. Top imports: Phenylephrine ($1.2M), Ranitidine ($191.5K).

Who supplies pharmaceuticals to Konark Intelmed Limited from India?

Konark Intelmed Limited sources from 1 verified Indian suppliers. The primary supplier is Euro Lifecare Private Limited (100.0% of imports, $10.1M).

What is Konark Intelmed Limited's total pharmaceutical import value?

Konark Intelmed Limited's total pharmaceutical import value from India is $1.4M, based on 86 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Konark Intelmed Limited focus on?

Konark Intelmed Limited imports across 2 categories. The largest: Respiratory & OTC (86.7%), Gastrointestinal (13.3%).

Get Full Konark Intelmed Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.